AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids

AbbVie announced positive data from the first of two pivotal Phase III studies testing the GnRH receptor antagonist, but Allergan and Myovant are among the companies also looking to bring new drugs to market.

airport runway under the sun as background

The first positive Phase III data from AbbVie Inc. and partner Neurocrine Biosciences Inc. for elagolix for the treatment of heavy menstrual bleeding in women with uterine fibroids puts pressure on competitors also looking to break into the emerging new drug treatment category. AbbVie announced data from the first of two Phase III studies testing elagolix in women with uterine fibroids Feb 21.

There are currently limited non-surgical treatments for heavy bleeding associated with uterine fibroids, but Allergan PLC and the

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category